Search: WFRF:(Hansson Lina S.)
> (2015-2019) >
Adjuvant chemothera...
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX)
-
- Hall, Kirsten Sundby (author)
- Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway,Oslo university hospital,Norwegian Radium Hospital
-
- Bruland, Oyvind S. (author)
- Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway;Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway,Oslo university hospital,Norwegian Radium Hospital,University of Oslo
-
- Bjerkehagen, Bodil (author)
- Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway,Norwegian Radium Hospital,Oslo university hospital
-
show more...
-
- Zaikova, Olga (author)
- Oslo Univ Hosp, Div Orthopaed Surg, Oslo, Norway,Oslo university hospital
-
- Engellau, Jacob (author)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Hagberg, Oskar (author)
- Reg Canc Ctr South, Lund, Sweden,Skåne University Hospital
-
- Hansson, Lina (author)
- Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden,Sahlgrenska University Hospital
-
- Hagberg, Hans (author)
- Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Uppsala Univ Hosp, Sweden,Uppsala University Hospital
-
- Ahlstrom, Marie (author)
- Lund Univ, Lund, Sweden;Skane Univ Hosp, Dept Oncol, Lund, Sweden,Lund University,Skåne University Hospital
-
- Knobel, Heidi (author)
- St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway,St. Olav’s University Hospital
-
- Papworth, Karin (author)
- Norrlands Univ Hosp, Dept Oncol, Umea, Sweden,Norrland University Hospital
-
- Zemmler, Maja (author)
- Linkoping Univ Hosp, Dept Oncol, Linkoping, Sweden,Region Östergötland, Onkologiska kliniken US,Linköping University Hospital
-
- Goplen, Dorota (author)
- Haukeland Hosp, Dept Musculoskeletal Tumour Serv Oncol, Bergen, Norway,Haukeland University Hospital
-
- Bauer, Henrik C. F. (author)
- Karolinska Institute
-
- Eriksson, Mikael (author)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
show less...
-
(creator_code:org_t)
- ELSEVIER SCI LTD, 2018
- 2018
- English.
-
In: European Journal of Cancer. - : ELSEVIER SCI LTD. - 0959-8049 .- 1879-0852. ; 99, s. 78-85
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy.Methods: High-risk STS was defined as high-grade morphology (according to the Federation Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II-III) and either vascular invasion or at least two of the following criteria: tumour size >= 8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m(2)) and ifosfamide (6 g/m(2)) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4.Results: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2-8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1-78.4) with a local recurrence rate of 14.0% (95% CI: 7.8-20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2-8.7). The five-year OS was 76.1% (95% CI: 68.8-84.2). Tumour size, deep location and reduced dose intensity (<80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death.Conclusions: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Soft tissue sarcoma
- Adjuvant treatment
- Prognostic factors
- Vascular invasion
- Growth pattern
- Tumour size
- Necrosis
- Survival
- Adjuvant treatment
- Growth pattern
- Necrosis
- Prognostic factors
- Soft tissue sarcoma
- Survival
- Tumour size
- Vascular invasion
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hall, Kirsten Su ...
-
Bruland, Oyvind ...
-
Bjerkehagen, Bod ...
-
Zaikova, Olga
-
Engellau, Jacob
-
Hagberg, Oskar
-
show more...
-
Hansson, Lina
-
Hagberg, Hans
-
Ahlstrom, Marie
-
Knobel, Heidi
-
Papworth, Karin
-
Zemmler, Maja
-
Goplen, Dorota
-
Bauer, Henrik C. ...
-
Eriksson, Mikael
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
European Journal ...
- By the university
-
Uppsala University
-
Karolinska Institutet
-
Linköping University
-
Lund University